Mersana Therapeutics (NASDAQ: MRSN) reported Q4 EPS of ($0.11), $0.04 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $16.36 million versus the consensus estimate of $7.38 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.